Avalo Therapeutics (AVTX) Income from Continuing Operations (2014 - 2026)
Avalo Therapeutics (AVTX) reported Income from Continuing Operations of 19630000.0 for Q1 2026, down 49.29% on a YoY basis from 38709488.6 in Q1 2025, and down 43.08% quarter-over-quarter from 13720000.0 in Q4 2025.
Avalo Therapeutics (AVTX) Income from Continuing Operations (2014 - 2026) Analysis & Trends
Avalo Therapeutics has reported Income from Continuing Operations for 13 years, with the latest figure at 19630000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 49.29% year-over-year to 19630000.0; the trailing twelve-month figure through Mar 2026 stood at 84740000.0 (down 216.06% YoY), and the FY2025 full-year result was 78259000.0, down 122.78% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 19630000.0, down from 13720000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 98463000.0 in Q2 2024, with the low at 121290000.0 in Q1 2024.
- Historically, Income from Continuing Operations has averaged 12130588.24 across 5 years, with a median of 12987000.0 in 2022.
- The largest YoY upside for Income from Continuing Operations was 1301.79% in 2024 against a maximum downside of 1118.38% in 2024.
- Avalo Therapeutics' Income from Continuing Operations stood at 9812000.0 in 2022, then grew by 16.75% to 8168000.0 in 2023, then sank by 332.65% to 35339000.0 in 2024, then surged by 61.18% to 13720000.0 in 2025, then plunged by 43.08% to 19630000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 19630000.0 (Q1 2026), 13720000.0 (Q4 2025), and 30625000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Avalo Therapeutics | 295.77 Mn | 295.77 Mn | - | -19.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.63 Mn |
| Dec 31, 2025 | -13.72 Mn |
| Sep 30, 2025 | -30.63 Mn |
| Jun 30, 2025 | -20.77 Mn |
| Mar 31, 2025 | -13.15 Mn |
| Dec 31, 2024 | -35.34 Mn |
| Sep 30, 2024 | 23.04 Mn |
| Jun 30, 2024 | 98.46 Mn |
| Mar 31, 2024 | -121.29 Mn |
| Dec 31, 2023 | -8.17 Mn |
| Sep 30, 2023 | -5.23 Mn |
| Jun 30, 2023 | -8.19 Mn |
| Mar 31, 2023 | -9.96 Mn |
| Dec 31, 2022 | -9.81 Mn |
| Sep 30, 2022 | 3.19 Mn |
| Jun 30, 2022 | -12.99 Mn |
| Mar 31, 2022 | -22.05 Mn |
| Dec 31, 2021 | -19.13 Mn |
| Sep 30, 2021 | -17.47 Mn |
| Jun 30, 2021 | -17.17 Mn |